Analysts predict the last quarter of FY18 to be mixed bag with revenues expected to remain almost flat to a growth of lower single digit on year-on-year basis. The net profit is predicted to decline by around 9-10 percent.

Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

As Indian drug makers brace up to report their third quarter earnings in the days ahead, analysts predict Q3 FY18 to be mixed bag with revenues expected to remain flat on year-on-year basis, though on sequential basis things may look much better.

GlaxoSmithKline profit rises 32% in Q2 led by recovery of inventory levels

The company posted Rs 99 crore in the year-ago quarter. Revenue for the quarter grew 5 percent to Rs 836 crore over the previous year.

Margins recovering; expect them to normalise around 20%: GSK

In an interview to CNBC-TV18, Andrew Aristidou, CFO of GlaxoSmithKline Pharmaceuticals spoke about the results and his outlook for the company.

Cos margins to outperform industry avg this fiscal: GSK Pharma

In an interview with CNBC-TV18, A Vaidheesh, VP, South Asia and MD of India GSK said that company‘s growth is in-line with the market and expects margins to outperform the industry average this fiscal.

GSK Pharma Q2 net may fall 20% at Rs 130.8cr: MOST

Sales of GlaxoSmithkline Pharmaceuticals are expected to increase by 10.8 percent Q-o-Q (up 5.5 percent Y-o-Y) to Rs 705.4 crore, according to Motilal Oswal.

GlaxoSmithKline Q2 declines 29.64% at Rs 115.04 cr

The company follows January to December financial year. GlaxoSmithKline Pharmaceuticals shares today closed at Rs 2,392 per scrip on BSE, up 2.98 per cent from its previous close.

Pharma cos likely to post 21% EBITDA growth in Q4: MOST

Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).

See pharma sector's Q3 topline to grow 22%: Motilal Oswal

Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.

HUL's packaged food segment may slowdown in Q2: StanChart

India‘s largest FMCG makes, Hindustan Unilever (HUL) would announce its second quarter earnings today. Sanjay Singh of Standard Chartered Securities expects the company‘s volumes to grow by 8 percent in Q2. However, he cautions that its packaged food category may see some slowdown.

GSK Pharma Sept qtr PAT seen up 5% at Rs 165.5 cr

Dolat Capital has come out with its earning estimates on Pharma sector for the quarter ended September 2011. According to the research firm, GSK Pharma September quarter net sales are expected to go up by 10.3% at Rs 650 crore, year-on-year, (YoY) basis.

GSK Pharma Jun qtr PAT seen up 21% at Rs 156cr: PINC

PINC Research has come out with its earning estimates on pharma sector for the quarter ended June 2011. According to the research firm, GlaxoSmithKline Pharmaceuticals June quarter net revenues are expected to go up by 12.6% at Rs 560.8 crore, year-on-year, (YoY) basis.

GSK Pharma Mar qtr PAT seen up at Rs 182.9 cr: MOST

Motilal Oswal has come out with its earning estimates on Pharmaceuticals sector for the quarter ended March 2011. According to the research firm, GSK Pharma March quarter sales are expected to go up by 16% at Rs 627.7 crore, year-on-year, (YoY) basis.

Business to grow Rs 1000cr in FY11: Stride Arcolab

Stride Arcolab announced it Q3 results for FY11. The company reported a consolidated net profit of Rs 122.4 crore for the year ended 2010 as against Rs 109.7 crore in previous year.

GSK Pharma Q4 PAT seen up 15% to Rs 123 cr

Healthcare company GlaxoSmithKline Pharmaceuticals (GSK Pharma) is set to report a profit after tax (PAT) of Rs 123 crore for the quarter ended December 2010, up 15% as compared to Rs 107.2 crore in same quarter the previous year, according to CNBC-TV18 estimates.

GSK Pharma Dec qtr PAT seen up 15% at Rs 119cr: Angel

Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, GlaxoSmithKline Pharmaceuticals December quarter net sales are expected to go up by 15% to Rs 511 crore, Year-on-Year, (Y-o-Y) basis.

GSK Pharma Dec qtr PAT seen up 11% at Rs 114.9cr: Karvy

Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, GlaxoSmithkline Pharma December quarter sales are expected to go up by 13.1% at Rs 509 crore, Year-on-Year, (YoY) basis.

GlaxoSmithKline Dec qtr PAT seen up at Rs 119.9cr: Emkay

Emkay Global Financial Services has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, GlaxoSmithKline December quarter sales are expected to go up by 14.3% to Rs 514.3 crore, Year-on-Year, (Y-o-Y) basis.